Following a September 2023 acquisition of 18,950,000 shares in Cybin, Point72 now has increased its share position to 30,061,112 total, as per a February 2024 Schedule 13G filing.
Point72, the investment firm led by billionaire hedge fund manager Steven A. Cohen has recently made a significant move that points to the growing recognition of Cybin’s efforts in revolutionizing mental healthcare. The firm filed a 13G, reporting ownership of more than 5% of Cybin’s total stock issue. This comes after the investment firm purchased almost 19 million shares in Cybin in September of last year. As it stands today, Point72 now holds 30,061,112 shares in the leading clinical-stage biopharmaceutical company.
Their position has increased by almost 60%, and this heightened involvement by Point72 comes at a time when Cybin is gaining traction in the mental healthcare realm with its innovative psychedelic-based treatments.
Recently, Cybin made significant strides in its research and development endeavors, particularly with its proprietary compounds CYB004 and CYB003 compounds, formulated to tackle Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) respectively.
The U.S. Food and Drug Administration (FDA) cleared Cybin’s investigational new drug (IND) application for CYB004 in January 2024. CYB004 is a deuterated dimethyltryptamine (DMT) molecule designed for treating GAD. This milestone paves the way for a Phase 2a study slated to commence in the first quarter of 2024.
The study aims to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CYB004 in individuals with GAD. If successful, CYB004 could offer a novel approach to managing this prevalent anxiety disorder, providing hope for patients and healthcare providers alike.
“With the recent positive topline results from two Phase 1 studies of our proprietary deuterated DMT molecules, CYB004 and SPL028, we are well-positioned to initiate a Phase 2a study of CYB004 in GAD this quarter,” said Doug Drysdale, Chief Executive Officer of Cybin in a press release.
“From our extensive portfolio of DMT and deuterated DMT datasets across five completed clinical studies, we have gathered important insights on dosing and preliminary efficacy signals in both depression and anxiety that will inform our next steps. Exploratory data from our completed Phase 2a study of SPL026 (IV DMT) have shown that SPL026 reduced symptoms of anxiety in patients with major depressive disorder, which further serves to de-risk the development of deuterated DMT in anxiety disorders as we continue to evaluate the efficacy and safety of CYB004,” he says.
Although anxiety disorders are one of the most prevalent mental health disorders, Drysdale emphasizes that current treatment options remain limited, with suboptimal response and remission rates. “We are committed to developing improved treatment options with the goal of improving the quality of life for people suffering from anxiety disorders worldwide,” he added.
The recent FDA clearance for CYB004’s investigational new drug application is a significant milestone that further solidifies Cybin’s position in the industry. As the company continues to make progress in clinical trials and regulatory milestones, the future of mental health treatment looks increasingly promising.
Additionally, Cybin now has a Topline Phase 2 data readout on CYB003, its unique deuterated psilocybin compound. 6 weeks following two doses of CYB003 (12mg), incremental Montgomery-Asberg Depression Rating Scale MADRS score reductions were seen with 79% of patients in remission from depression.
With this data readout, CYB003 achieved its primary efficacy endpoint with a -14 point difference in MADRS score reduction from the baseline between the 12mg dose vs. placebo at 3 weeks. Reachers saw a “rapid, robust, and clinically significant deduction of depression symptoms” following a single dose of CYB003, with a “clear incremental benefit of a second dose.”
Most importantly, CYB003 was shown to have a favorable safety and tolerability profile with no treatment-related serious adverse events at 12mg and 16mg doses.
With impressive results like these, Cybin drives into 2024 ready to continue clinical trials for both CYB003 and CYB004.
Through the convergence of science, innovation, and investment, Cybin is paving the way for a brighter future in mental healthcare. The partnership with Point72, led by Steven A. Cohen, further amplifies Cybin’s efforts to revolutionize mental healthcare.
After initially acquiring shares last September, Point72 kicks off 2024 by doubling down. Now holding over 7% of Cybin, Steven A. Cohen’s investment firm is taking a strong stand in the biopharmaceutical space
This strategic alliance not only underscores the growing recognition of Cybin’s groundbreaking initiatives but also injects fresh momentum into its research and development endeavors. With Point72’s backing, Cybin is well-equipped to accelerate its efforts, expand its reach, and deliver much-needed relief to individuals grappling with mental health disorders.
To learn more about Cybin, be sure to visit their website today.
